Dynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. grew its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 18.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,016 shares of the biopharmaceutical company’s stock after acquiring an additional 4,532 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Dynavax Technologies were worth $406,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Natixis Advisors L.P. boosted its stake in shares of Dynavax Technologies by 10.5% during the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 1,804 shares in the last quarter. SummerHaven Investment Management LLC increased its stake in Dynavax Technologies by 1.5% during the 4th quarter. SummerHaven Investment Management LLC now owns 52,973 shares of the biopharmaceutical company’s stock worth $741,000 after acquiring an additional 799 shares during the period. New York State Common Retirement Fund boosted its holdings in shares of Dynavax Technologies by 5.7% during the 4th quarter. New York State Common Retirement Fund now owns 52,725 shares of the biopharmaceutical company’s stock valued at $737,000 after acquiring an additional 2,860 shares in the last quarter. Illinois Municipal Retirement Fund lifted its stake in shares of Dynavax Technologies by 8.9% in the 4th quarter. Illinois Municipal Retirement Fund now owns 77,139 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 6,333 shares during the period. Finally, Handelsbanken Fonder AB grew its holdings in shares of Dynavax Technologies by 3.4% in the fourth quarter. Handelsbanken Fonder AB now owns 27,300 shares of the biopharmaceutical company’s stock valued at $382,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Shares of DVAX stock traded down $0.64 on Thursday, hitting $11.01. 4,557,601 shares of the company’s stock were exchanged, compared to its average volume of 2,045,772. The stock has a market cap of $1.44 billion, a P/E ratio of -179.83 and a beta of 1.30. The company has a 50 day moving average of $12.06 and a 200 day moving average of $13.03. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96. Dynavax Technologies Co. has a 12 month low of $10.48 and a 12 month high of $15.15.

Insider Activity

In other news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Thursday. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. Finally, StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Dynavax Technologies has a consensus rating of “Moderate Buy” and an average target price of $25.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.